CLINICAL_TRIALS
trial_result
· 2016-02-29
Clinical Trial Update: BEZ235 in Patients With Advanced Renal Cell Carcinoma (RCC) [Phase 1, Phase 2]
Summary
A Phase 1/2 clinical trial of BEZ235 (dactolisib) in patients with advanced renal cell carcinoma was terminated, with results posted in February 2016.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Renal Cancer | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2016-02-29